Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan:601:110285.
doi: 10.1016/j.virol.2024.110285. Epub 2024 Nov 5.

Strengths and limitations of SARS-CoV-2 virus-like particle systems

Rokaia Sultana  1 , Robert V Stahelin  2
Affiliations
Review

Strengths and limitations of SARS-CoV-2 virus-like particle systems

Rokaia Sultana et al. Virology. 2025 Jan.

Abstract

Virus-like particles (VLPs) resemble the parent virus but lack the viral genome, providing a safe and efficient platform for the analysis of virus assembly and budding as well as the development of vaccines and drugs. During the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the formation of SARS-CoV-2 VLPs was investigated as an alternative to authentic virions because the latter requires biosafety level 3 (BSL-3) facilities. This allowed researchers to model its assembly and budding processes, examine the role of mutations in variants of concern, and determine how the structural proteins interact with each other. Also, the absence of viral genome in VLPs circumvents worries of gains in infectivity via mutagenesis. This review summarizes the strengths and limitations of several SARS-CoV-2 VLP systems and details some of the strides that have been made in using these systems to study virus assembly and budding, viral entry, and antibody and vaccine development.

Keywords: Coronavirus; Envelope protein; Membrane protein; Nucleoprotein; SARS-CoV-2; Spike protein; Virus assembly; Virus budding; Virus-like particle.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors have no competing interests to declare.

Similar articles

See all similar articles

Cited by

References

    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, … & Tan W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine, 382 (8), 727–733. - PMC - PubMed
    1. Carfì A, Bernabei R, & Landi F. (2020). Persistent symptoms in patients after acute COVID-19. Jama, 324 (6), 603–605. - PMC - PubMed
    1. Tenforde MW (2020). Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020. MMWR. Morbidity and mortality weekly report, 69. - PMC - PubMed
    1. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, … & Cao B. (2023). 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet, 401 (10393), e21–e33. - PMC - PubMed
    1. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, … & Wan EY. (2021). Post-acute COVID-19 syndrome. Nature medicine, 27 (4), 601–615. - PMC - PubMed

Publication types

LinkOut - more resources